Sumitomo Mitsui Trust Holdings Inc. Cuts Position in Repligen Co. (NASDAQ:RGEN)

Sumitomo Mitsui Trust Holdings Inc. reduced its position in shares of Repligen Co. (NASDAQ:RGEN) by 2.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 108,912 shares of the biotechnology company’s stock after selling 2,613 shares during the period. Sumitomo Mitsui Trust Holdings Inc. owned 0.20% of Repligen worth $19,582,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. Artisan Partners Limited Partnership increased its stake in Repligen by 11.3% during the 3rd quarter. Artisan Partners Limited Partnership now owns 1,556,873 shares of the biotechnology company’s stock worth $247,558,000 after buying an additional 157,807 shares in the last quarter. Wellington Management Group LLP increased its stake in Repligen by 2.1% during the 3rd quarter. Wellington Management Group LLP now owns 1,396,610 shares of the biotechnology company’s stock worth $222,075,000 after buying an additional 29,215 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Repligen by 13.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 1,195,629 shares of the biotechnology company’s stock worth $190,117,000 after buying an additional 137,220 shares in the last quarter. Conestoga Capital Advisors LLC increased its stake in Repligen by 0.4% during the 4th quarter. Conestoga Capital Advisors LLC now owns 709,738 shares of the biotechnology company’s stock worth $127,611,000 after buying an additional 2,590 shares in the last quarter. Finally, Parnassus Investments LLC purchased a new stake in Repligen during the 3rd quarter worth approximately $87,475,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Repligen Trading Up 0.2 %

RGEN opened at $157.48 on Tuesday. Repligen Co. has a one year low of $110.45 and a one year high of $211.13. The stock has a market capitalization of $8.79 billion, a PE ratio of 218.73, a P/E/G ratio of 5.15 and a beta of 1.02. The business’s 50 day moving average price is $187.16 and its 200 day moving average price is $173.44. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.75 and a current ratio of 7.02.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $0.33 EPS for the quarter, meeting analysts’ consensus estimates of $0.33. Repligen had a return on equity of 5.00% and a net margin of 6.51%. The firm had revenue of $155.74 million for the quarter, compared to analysts’ expectations of $155.38 million. During the same period in the prior year, the firm posted $0.68 earnings per share. The firm’s quarterly revenue was down 16.6% on a year-over-year basis. As a group, equities research analysts expect that Repligen Co. will post 1.46 EPS for the current year.

Insider Activity at Repligen

In related news, VP Ralf Kuriyel sold 3,517 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $193.73, for a total value of $681,348.41. Following the transaction, the vice president now directly owns 24,260 shares in the company, valued at $4,699,889.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Repligen news, VP Ralf Kuriyel sold 3,517 shares of the company’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $193.73, for a total transaction of $681,348.41. Following the transaction, the vice president now directly owns 24,260 shares in the company, valued at $4,699,889.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO James Bylund sold 4,373 shares of the company’s stock in a transaction on Friday, February 23rd. The stock was sold at an average price of $198.08, for a total value of $866,203.84. Following the transaction, the chief operating officer now owns 14,135 shares in the company, valued at $2,799,860.80. The disclosure for this sale can be found here. Over the last three months, insiders have sold 25,597 shares of company stock worth $5,039,532. Insiders own 1.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on RGEN. KeyCorp upped their price target on Repligen from $210.00 to $220.00 and gave the company an “overweight” rating in a research report on Thursday, February 15th. Stifel Nicolaus upped their price target on Repligen from $165.00 to $207.00 and gave the company a “buy” rating in a research report on Thursday, February 22nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $196.70.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.